-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Setanaxib in Kidney Disease (Nephropathy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Setanaxib in Kidney Disease (Nephropathy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Setanaxib in Kidney Disease (Nephropathy) Drug Details: Setanaxib (GKT-831; GKT-137831)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Setanaxib in Alport Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Setanaxib in Alport Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Setanaxib in Alport Syndrome Drug Details: Setanaxib (GKT-831; GKT-137831) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Setanaxib in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Setanaxib in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Setanaxib in Primary Biliary Cholangitis (Primary Biliary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Setanaxib in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Setanaxib in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Setanaxib in Recurrent Head And Neck...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Setanaxib in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Setanaxib in Recurrent Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Setanaxib in Recurrent Head And Neck...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Setanaxib in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Setanaxib in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Setanaxib in Primary Biliary Cholangitis (Primary Biliary...
-
Product Insights
CAF/ Comm Engineers & Body Builders – Metro Coach Manufacturing Plant – India
Equip yourself with the essential tools needed to make informed and profitable decisions with our CAF/ Comm Engineers & Body Builders - Metro Coach Manufacturing Plant - India report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Company Profile
Construcciones y Auxiliar de Ferrocarriles SA – Company Profile
Construcciones y Auxiliar de Ferrocarriles SA (CAF) manufactures and supplies railway vehicles. The company offers rolling stock, and buses. Its product portfolio consists of high speed trains, commuter, light rail vehicles, metro, locomotives, trams, and conventional and electric buses. The company also offers a diverse range of rail services such as maintenance, refurbishment and upgrading, and project management, auxiliary vehicle service and after sales services. It also operates manufacturing units in Spain, France, the US, Mexico and Brazil. The company...
Add to Basket -
Thematic Analysis
Emerging Economies in Sport – Thematic Intelligence
Emerging Economies in Sport Thematic Overview Historically, the global economy was largely dominated by the European and North American countries, however, the landscape has been slowly shifting in the last couple of decades. Certain Asian countries, including India and China, have been growing their economy rapidly and are starting to play a bigger role. The growth of the Chinese business market is staggering. The country now boasts some of the most valuable and profitable companies in the world, notably Alibaba...
-
Track & Monitor
PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2018 Edition
This report is the 8th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.